Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LID104 in Type 2 Diabetes Mellitus
NCT05886088Phase 3Not yet recruiting
- Sponsor
- EMS
- Start
- Feb 2024
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dapagliflozin + linagliptin + metformin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by EMS. Primary endpoint: Glycated hemoglobin at 120 days. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
dapagliflozin + linagliptin + metformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05886088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05886088.